Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
147
-
Total 13F shares, excl. options
-
18.8M
-
Shares change
-
-605K
-
Total reported value, excl. options
-
$829M
-
Value change
-
-$26.9M
-
Put/Call ratio
-
2.37
-
Number of buys
-
63
-
Number of sells
-
-74
-
Price
-
$44.01
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2021
168 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q2 2021.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 147 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.8M shares
of 27.8M outstanding shares and own 67.8% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.67M shares), ARMISTICE CAPITAL, LLC (2M shares), Farallon Capital Management LLC (2M shares), VANGUARD GROUP INC (1.86M shares), STATE STREET CORP (1.05M shares), Krensavage Asset Management, LLC (940K shares), RENAISSANCE TECHNOLOGIES LLC (798K shares), NORTHERN TRUST CORP (649K shares), DIMENSIONAL FUND ADVISORS LP (645K shares), and ACADIAN ASSET MANAGEMENT LLC (367K shares).
This table shows the top 147 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.